The lineup covers investigational obesity drugs, real-world Wegovy results and semaglutide studies in kids aged 6 to under 12.
Recap by typeshit. Full story at Voice of Healthcare.
A Facebook share says Danish teams found certain bacterial strains may change how the gut tells the brain it is full. The work so far is in animal models only.
Bikman calls the results remarkable, but he argues that bigger drops make it more important to know how much of the lost weight is fat and how much is muscle.
Bikman points out that weight usually returns once the drug is stopped, which makes the question of lifelong use a real one.
Avi Roy flags a preprint that pooled 10,052 people from five semaglutide trials and used a blood test to estimate heart age. It has not yet been peer reviewed.
Local 12 reports the chain is looking at menu options aimed at people taking GLP-1 medications. Details are in the linked report.
The account calls the up to 28% weight loss impressive but says only about half of participants finished, citing nausea, constipation and skin sensitivity.
Loading…